Nivolumab cuts relapse by one third compared to Ipilimumab
European Pharmaceutical Review | September 11, 2017
The immunotherapy drug nivolumab is safer and more effective than ipilimumab the current standard of care in treating patients with resected stage III and stage IV melanoma, according to an international clinical trial the study involved two groups of 453 participants–one treated with nivolumab and the other treated with ipilimumab.